Recap: DexCom Q2 Earnings

Shares of DexCom DXCM increased 1% in after-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share were up 887.50% year over year to $0.79, which beat the estimate of $0.35.

Revenue of $451,800,000 rose by 34.30% year over year, which beat the estimate of $415,390,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

The upcoming fiscal year's revenue expected to be between $1,850,000,000 and $1,850,000,000.

How To Listen To The Conference Call

Date: Jul 28, 2020

Time: 04:30 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/e6y8exrx

Price Action

Company's 52-week high was at $446.50

52-week low: $138.28

Price action over last quarter: Up 22.44%

Company Profile

Dexcom designs and commercializes continuous glucose monitoring (CGM) systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company sells three different pieces of equipment, a sensor, a transmitter, and a receiver.